Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. 2004

Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
Department of Hematology and Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Medicine, Sapporo Hokuyu Hospital, Sapporo, Japan. jutanaka@med.hokudai.ac.jp

Inhibitory natural killer cell receptor (NKR)-expressing cells may induce a graft-versus-leukemia/tumor (GVL/T) effect against leukemic cells and tumor cells that have mismatched or decreased expression of HLA class I molecules and may not cause graft-versus-host disease (GVHD) against host cells that have normal expression of HLA class I molecules. In our study, we were able to expand inhibitory NKR (CD94/NKG2A)-expressing CD8+ T cells from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (G-PBMCs) by more than 500-fold using stimulation by an anti-CD3 monoclonal antibody with interleukin 15 (IL-15). These expanded and purified CD94-expressing cells attacked various malignant cell lines, including solid cancer cell lines, as well as the patients' leukemic cells but not autologous and allogeneic phytohemagglutinin (PHA) blasts in vitro. Also, these CD94-expressing cells prevented the growth of K562 leukemic cells and CW2 colon cancer cells in NOD/SCID mice in vivo. On the other hand, the CD94-expressing cells have low responsiveness to alloantigen in mixed lymphocyte culture (MLC) and have high transforming growth factor (TGF)-beta1- but low IL-2- producing capacity. Therefore, CD94-expressing cells with cytolytic activity against the recipient's leukemic and tumor cells without enhancement of alloresponse might be able to be expanded from donor G-PBMCs.

UI MeSH Term Description Entries
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013234 Stem Cells Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells. Colony-Forming Units,Mother Cells,Progenitor Cells,Colony-Forming Unit,Cell, Mother,Cell, Progenitor,Cell, Stem,Cells, Mother,Cells, Progenitor,Cells, Stem,Colony Forming Unit,Colony Forming Units,Mother Cell,Progenitor Cell,Stem Cell
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
July 2000, Bone marrow transplantation,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
March 1997, Blood,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
August 1997, Blood,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
August 1997, Blood,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
January 2012, Cell transplantation,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
August 1994, Experimental hematology,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
October 1997, Blood,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
February 2006, Diabetes care,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
September 2005, Diabetes care,
Junji Tanaka, and Tomomi Toubai, and Yutaka Tsutsumi, and Yoko Miura, and Naoko Kato, and Shintarou Umehara, and Kaoru Kahata, and Akio Mori, and Nobuyasu Toyoshima, and Shuichi Ota, and Takahiko Kobayashi, and Masanobu Kobayashi, and Masaharu Kasai, and Masahiro Asaka, and Masahiro Imamura
July 2013, Cytotherapy,
Copied contents to your clipboard!